E74.82 Category · further specificity required Disorders of citrate metabolism

ICD-10-CM E74.82 identifies “Disorders of citrate metabolism” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.

Chapter 4: Endocrine, nutritional and metabolic diseases

Code-level instructions

No additional notes.

Inherited instructions

Chapters 4 · Endocrine, nutritional and metabolic diseases (E00-E89)

Excludes 11

transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Note1

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

E70-E88 · Metabolic disorders (E70-E88)

Excludes 15
  • androgen insensitivity syndrome (E34.5-)
  • congenital adrenal hyperplasia (E25.0)
  • hemolytic anemias attributable to enzyme disorders (D55.-)
  • Marfan syndrome (Q87.4-)
  • 5-alpha-reductase deficiency (E29.1)
Excludes 21

Ehlers-Danlos syndromes (Q79.6-)

E74 · Other disorders of carbohydrate metabolism

Excludes 14
  • diabetes mellitus (E08-E13)
  • hypoglycemia NOS (E16.2)
  • increased secretion of glucagon (E16.3)
  • mucopolysaccharidosis (E76.0-E76.3)

More specific codes

Official index references
History

Code history

Latest recorded change · FY2025

ChangedUnchanged
FY2025

Effective from

  • Added

Disorders of citrate metabolism

Category — select a more specific code

CDC/NCHS · FY2025

All editions (5)

All editionsEffective fromCode history
FY20252024-10-01Added
FY2025 · 04-012025-04-01No tabular change
FY20262025-10-01No tabular change
FY2026 · April2026-04-01No tabular change
FY20272026-10-01No tabular change

Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.